NO862537L - Ny analyse for, og rensing av, amyloidkomponenter og anvendelser derav. - Google Patents

Ny analyse for, og rensing av, amyloidkomponenter og anvendelser derav.

Info

Publication number
NO862537L
NO862537L NO862537A NO862537A NO862537L NO 862537 L NO862537 L NO 862537L NO 862537 A NO862537 A NO 862537A NO 862537 A NO862537 A NO 862537A NO 862537 L NO862537 L NO 862537L
Authority
NO
Norway
Prior art keywords
sap
saa
carrier
solutions
phenyl groups
Prior art date
Application number
NO862537A
Other languages
English (en)
Norwegian (no)
Other versions
NO862537D0 (no
Inventor
Dan Serban
Christiane Rordorf
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO862537D0 publication Critical patent/NO862537D0/no
Publication of NO862537L publication Critical patent/NO862537L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/545—Synthetic resin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/805—Test papers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809—Multifield plates or multicontainer arrays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/81—Tube, bottle, or dipstick
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y10S530/814—Cellulose or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO862537A 1985-06-25 1986-06-24 Ny analyse for, og rensing av, amyloidkomponenter og anvendelser derav. NO862537L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB858516081A GB8516081D0 (en) 1985-06-25 1985-06-25 Assay & purification of amyloid components

Publications (2)

Publication Number Publication Date
NO862537D0 NO862537D0 (no) 1986-06-24
NO862537L true NO862537L (no) 1986-12-29

Family

ID=10581309

Family Applications (1)

Application Number Title Priority Date Filing Date
NO862537A NO862537L (no) 1985-06-25 1986-06-24 Ny analyse for, og rensing av, amyloidkomponenter og anvendelser derav.

Country Status (12)

Country Link
US (1) US4782014A (fr)
EP (1) EP0206302A3 (fr)
JP (1) JPS622161A (fr)
AU (1) AU5915186A (fr)
DK (1) DK297086A (fr)
ES (2) ES8802197A1 (fr)
FI (1) FI862595L (fr)
GB (1) GB8516081D0 (fr)
GR (1) GR861603B (fr)
IL (1) IL79199A0 (fr)
NO (1) NO862537L (fr)
ZA (1) ZA864698B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965187A (en) * 1986-09-10 1990-10-23 Idexx Corporation Method and apparatus for assaying whole blood
SE454299B (sv) * 1986-10-08 1988-04-18 Westermark P Sats innehallande polypeptid som finns i pankreasoamyloid och/eller antikroppar riktade mot polypeptiden
US5206136A (en) * 1986-11-19 1993-04-27 Genetic Systems Corporation Rapid membrane affinity concentration assays
CA1304682C (fr) * 1986-11-19 1992-07-07 Nobuo Monji Dosage immunologique permettant de mesurer les concentrations par affinite sur membrane
US5241012A (en) * 1987-05-19 1993-08-31 Applied Immune Sciences, Inc. Activated and conjugated polystyrene substrate
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
DE3880647T2 (de) * 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
FR2629916B1 (fr) * 1988-04-08 1992-09-04 Hoechst Behring Applic Pharmac Support solide pour diagnostic immunologique, son procede de traitement et application au diagnostic immunologique
US6287793B1 (en) * 1988-08-19 2001-09-11 Elan Pharmaceuticals, Inc. Diagnostic methods for alzheimer's disease
US5092876A (en) * 1989-08-30 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Cell attachment peptides derived from amyloid P component
US5262303A (en) * 1989-10-13 1993-11-16 Trustees Of Boston University Ligand/anti-ligand assays for adherent proteins
US5714140A (en) * 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
EP0500921B1 (fr) * 1990-09-11 1999-05-19 The Regents Of The University Of California Substances natriuretiques inhibant la na-k-atpase
CA2052316C (fr) * 1990-10-10 1997-12-23 Edward A. Oakley Systeme de mesure de l'ecoulement des boues
US5245017A (en) * 1991-05-31 1993-09-14 Applied Biotechnology, Inc. Method for isolating CEA-binding protein
US5278290A (en) * 1991-05-31 1994-01-11 Applied Biotechnology, Inc. Binding protein for CEA and uses thereof
US5281697A (en) * 1991-05-31 1994-01-25 Applied Biotechnology, Inc. CEA-binding protein and uses thereof
WO1992021364A1 (fr) * 1991-05-31 1992-12-10 New England Deaconess Hospital Corporation Proteines de liaison d'antigene carcinoembryonnaire et leurs procedes d'isolation et d'utilisation
US5358852A (en) * 1992-12-21 1994-10-25 Eastman Kodak Company Use of calcium in immunoassay for measurement of C-reactive protein
CA2164498C (fr) 1993-07-09 2007-09-11 Paul A. Price Essai pour ykl-40 comme marqueur de la degradation des constituants du tissu conjonctif de mammiferes
US6898532B1 (en) 1995-06-07 2005-05-24 Biomerieux, Inc. Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample
US6429017B1 (en) * 1999-02-04 2002-08-06 Biomerieux Method for predicting the presence of haemostatic dysfunction in a patient sample
US6321164B1 (en) 1995-06-07 2001-11-20 Akzo Nobel N.V. Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade
DE69607176T2 (de) * 1995-07-21 2000-09-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper
WO1999006838A2 (fr) * 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouveau procede pour detecter des agregats de proteines ou des fibrilles du type amyloide
WO1999006545A2 (fr) 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition et nouveau procede pour depister les maladies dues a la formation d'agregats de proteines ou de fibrilles du type amyloide
US6502040B2 (en) 1997-12-31 2002-12-31 Biomerieux, Inc. Method for presenting thrombosis and hemostasis assay data
US7595199B1 (en) 1998-07-31 2009-09-29 Max-Planck-Gesellschaft zur Förderung der Wissenchaften e.V. Method of detecting amyloid-like fibrils or protein aggregates
DE60015726T2 (de) * 1999-02-04 2005-12-22 Biomerieux, Inc. Verfahren und vorrichtung zum vorhersagen von haemostatischer funktionsstörung in patientenproben
US6251624B1 (en) 1999-03-12 2001-06-26 Akzo Nobel N.V. Apparatus and method for detecting, quantifying and characterizing microorganisms
US7179612B2 (en) * 2000-06-09 2007-02-20 Biomerieux, Inc. Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality
US7763256B2 (en) * 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US20100297074A1 (en) * 2002-12-23 2010-11-25 Richard Hans Gomer Wound healing compositions, systems, and methods
JP4922560B2 (ja) 2002-12-23 2012-04-25 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞への分化の検出方法、線維症を抑制する組成物および方法
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
JP5220025B2 (ja) * 2006-12-04 2013-06-26 プロメディオール， インコーポレイテッド 線維症疾患を処置するための併用療法
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
PT2405929T (pt) * 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) * 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
FR2969153B1 (fr) * 2010-12-17 2014-10-17 Lab Francais Du Fractionnement Procede de purification de proteine amyloide p et utilisation de la proteine ainsi purifiee
WO2013188529A1 (fr) 2012-06-15 2013-12-19 Temple University Of The Commonwealth System Of Higher Education Utilisation d'amyloïdes bactériens isolés pour le traitement de troubles ou de maladies inflammatoires de l'épithélium

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264766A (en) * 1877-09-19 1981-04-28 Hoffmann-La Roche Inc. Immunological diagnostic reagents
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4504585A (en) * 1982-04-05 1985-03-12 Aalto Scientific, Ltd. Affinity immunoassay system
US4683135A (en) * 1983-07-27 1987-07-28 Yeda Research And Development Co., Ltd. DSCG binding protein and process for preparing same
US4677057A (en) * 1985-03-11 1987-06-30 Scripps Clinic And Research Foundation Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis

Also Published As

Publication number Publication date
ES556534A0 (es) 1988-04-01
GB8516081D0 (en) 1985-07-31
FI862595A0 (fi) 1986-06-18
JPS622161A (ja) 1987-01-08
IL79199A0 (en) 1986-09-30
DK297086D0 (da) 1986-06-24
GR861603B (en) 1986-10-20
US4782014A (en) 1988-11-01
ES8802197A1 (es) 1988-04-01
NO862537D0 (no) 1986-06-24
ES8802618A1 (es) 1988-09-16
EP0206302A3 (fr) 1987-07-29
AU5915186A (en) 1987-01-08
ES557795A0 (es) 1988-09-16
ZA864698B (en) 1987-02-25
FI862595A7 (fi) 1986-12-26
DK297086A (da) 1986-12-26
EP0206302A2 (fr) 1986-12-30
FI862595L (fi) 1986-12-26

Similar Documents

Publication Publication Date Title
US4782014A (en) Assay and purification of amyloid components, applications, and kits therefor
Gosslau et al. Enzyme-linked immunosorbent microassay for quantification of specific antibodies to collagen type I, II, III
EP0450099B1 (fr) Excipient de liaison d'anticorps antiphospholipides, immuno-analyse utilisant cet excipient et kit associe
EP0196787B2 (fr) Procédé de détection des aflatoxines
US4239743A (en) Carrier-bound immunoglobulin fission product and its use in immunologic analyses
JP2517187B2 (ja) アナライト変異体分析
US4722890A (en) Quantitative assay for human terminal complement cascade activation
US4859611A (en) Affinity column and process for detection of low molecular weight toxic substances
EP0585346A1 (fr) Determination d'alh (antigenes de leucocytes humains)
JPH0664060B2 (ja) 分析物の検出法及び検出剤
Mariotti et al. A new solid phase immunoradiometric assay for antithyroid microsomal antibody
Giallongo et al. Enzyme and radioimmunoassays for specific murine IgE and IgG with different solid-phase immunosorbents
EP0221282B1 (fr) Essai sandwich récepteur-anticorps
JP2669703B2 (ja) 測定法、用途及び構成部品
Serban et al. Quantitation of serum amyloid P component by an enzyme-linked immunoassay
CA2081900A1 (fr) Antigene endometrial, composition, trousse d'analyse et methode servant a determiner les anticorps endometriaux
US4820635A (en) Kit for assaying activation of terminal complement cascade
Schirrmacher The synthesis of radioactively labeled sulfanyl‐N‐chloracetyl tyrosine and its use for determinations of quantities and affinities of anti‐p‐azobenzenesulfonate antibodies
Avrameas Heterogeneous enzyme immunoassays
WO1999041611A1 (fr) Analyse d'anticorps diriges contre un ou plusieurs antigenes de helicobacter pylori dans des liquides biologiques au moyen d'une procede immunologique heterogene de type inverse
RU2164027C2 (ru) Способ определения состояния печени
EP0670040A1 (fr) Immobilisation de proteines chimiquement reticulees sur des supports solides
Mutchnick et al. Measurement of thymosin α1 by disassociation microELISA
Tienhaara et al. Double monoclonal time-resolved immunofluorometric assay of beta 2-microglobulin in serum
Akman et al. An Enzymeimmunoassay for total Thyroxine using avidin-biotin separation system and Thyroxine-Peroxidase conjugate